# US 7,666,431 B2 · Compositions and methods for the inhibition of membrane fusion by paramyxoviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,666,431 B2
- Document ID: US7666431B2
- Status: Granted
- Kind: B2
- Application number: 10/528,800
- Filed: 2002-11-13
- Published: 2006-10-19
- Granted: 2010-02-23
- Earliest claimed: 2001-11-13
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Christopher C. Broder; Katharine N. Bossart
- Web page: https://patentgrep.com/patent/US7666431B2

## CPC

- A61K 38/162: {from virus}
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2760/18222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18233: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a heptad portion of a Henipavirus F protein effective against fusion between a membrane of a paramyxovirus and a plasma membrane of a cell. The instant invention also provides nucleic acids, compositions, and methods effective against paramyxovirus infection. Accordingly, the instant invention provides therapeutic agents and vaccines effective against paramyxoviruses viruses, especially HeV or NiV.

## Claims

### Claim 1

A method for inhibiting fusion between a membrane of a Hendra or Nipah virus and a plasma membrane of a cell comprising administering to a subject in need thereof a composition comprising an effective amount of at least one polypeptide sequence consisting of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein said virus is Nipah virus (NiV).

### Claim 3 (depends on 1)

The method of claim 1, wherein said virus is Hendra virus (HeV).

### Claim 4

A method of inducing an immune response to a Hendra or Nipah virus, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising at least one polypeptide selected from the group consisting of:
(a) a polypeptide consisting of SEQ ID NO: 1; and
(b) a polypeptide consisting of SEQ ID NO: 2.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 1.

### Claim 6 (depends on 4)

The method of claim 4, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 2.

### Claim 7 (depends on 4)

The method of claim 4, wherein the subject is human.

### Claim 8 (depends on 4)

The method of claim 4, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition is formulated for oral administration, subcutaneous injection, intravenous injection, intramuscular injection, or intraperitoneal injection.

### Claim 10 (depends on 4)

The method of claim 4, wherein the composition is formulated as an immunogenic composition.

### Claim 11 (depends on 4)

The method of claim 4, wherein said virus is Nipah virus (NiV).

### Claim 12 (depends on 4)

The method of claim 4, wherein said virus is Hendra virus (HeV).